MedPath

The role of progesterone in ovulatio

Phase 3
Conditions
Infertility.
Female infertility associated with anovulation
N97.0
Registration Number
IRCT20240506061667N1
Lead Sponsor
Iranian academic center for education culture and research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
36
Inclusion Criteria

1. Patient age 20-35 years 2. Hysterosalpingography is normal in IUI group patients 3. Vaginal ultrasound is normal 4. Thyroid, prolactin, sugar and CBC tests are normal 5. AMH above 2 6. Genetic or autoimmune disease has been diagnosed

Exclusion Criteria

1. egg donation clients whose IVF cycle is canceled due to lack of suitable follicles (10-15) 2. history of ovarian cyst and endometriosis 3. patient unwillingness 4. immune and rheumatic disease 5. sensitivity to progesterone

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary Outcome Study of LH Surge Occurrence. Timepoint: It is at 12 and 36 hours after injection. Method of measurement: In the ultrasound before the intervention, as well as the serum level of FSH, progesterone and estrogen at 12 and 36 hours after the injection.
Secondary Outcome Measures
NameTimeMethod
The secondary outcome is the total number of eggs obtained. Timepoint: It is at 12 and 36 hours after injection. Method of measurement: In the ultrasound before the intervention, as well as the serum level of FSH, progesterone and estrogen at 12 and 36 hours after the injection.
© Copyright 2025. All Rights Reserved by MedPath